Tizanidine
Product Images NDC 71610-167

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 71610-167). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 4 mg (71610 0167 30)

Label for Tizanidine, USP 4 mg tablets featuring 30 tablets per bottle. The label includes storage instructions, repackaging information by Aphena Pharma Solutions - Tennessee, LLC in Cookeville, TN, and manufacturer details from Alkaloida Chemical Company Zrt., Kabay Janos, Hungary. Noted as prescription only (RX Only) with visible barcode and NDC 71610-0167-30.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Tizanidine-1 (Tizanidine 1)

Chemical structure of tizanidine hydrochloride showing a chlorinated thiazole ring fused with imidazoline and additional nitrogen-containing rings.*

FDA Label Image

Tizanidine-2 (Tizanidine 2)

A pharmacokinetic line graph depicting plasma tizanidine concentration (ng/mL) over time (hours) from dosing, comparing 4 mg tizanidine tablets and capsules both with and without food. Four distinct curves represent each condition, showing concentration peaks around 1-2 hours post-dose and gradual decline thereafter up to 24 hours.*

FDA Label Image

Tizanidine-3 (Tizanidine 3)

A line graph depicting improvement in Ashworth Score over 6 hours post-dose for Tizanidine at 8 mg and 16 mg doses compared to placebo. The y-axis represents improvement levels, and the x-axis shows time in hours after dosing. Error bars indicate variability in measurements.*

FDA Label Image

Tizanidine-4 (Tizanidine 4)

A line graph comparing the improvement in Ashworth Score over time for Tizanidine (mean dose 28.8 mg) versus placebo. The graph shows data points with error bars at End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (Last Observation Carry Forward), illustrating greater improvement for Tizanidine compared to placebo across all time points.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.